While we are unable to rule out the possibility that antibody-induced thrombocytopenia contributes to some of the therapeutic effect, it seems reasonable to suggest that thrombocytopenia-independent mechanisms likely contribute to the primary ameliorative actions of CD44 antibodies. This evidence concerns the gene CD44 and Thrombocytopenia.